Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2019 | 09-2019 | 06-2019 | 03-2019 | 12-2018 | |
| Sales | 69,555 | 91,977 | 100,803 | 72,666 | 59,850 |
| Cost of Goods | 38,147 | 38,263 | 37,669 | 31,257 | N/A |
| Gross Profit | 31,408 | 53,714 | 63,134 | 41,409 | 52,082 |
| Operating Expenses | 126,446 | 109,882 | 123,326 | 117,635 | 150,008 |
| Operating Income | -94,891 | -55,905 | -59,523 | -75,969 | -90,158 |
| Interest Expense | -307 | 0 | -485 | 0 | 0 |
| Other Income | -1,651 | 43 | 23 | 791 | 1,766 |
| Pre-tax Income | -96,235 | -55,862 | -59,015 | -75,178 | -88,392 |
| Income Tax | -1,752 | -1,277 | -845 | -2,757 | N/A |
| Net Income Continuous | -94,483 | -54,585 | -58,170 | -72,421 | -60,054 |
| Net Income | $-94,483 | $-54,585 | $-58,170 | $-72,421 | $-60,054 |
| EPS Basic Total Ops | -0.79 | -0.46 | -0.49 | -0.62 | -0.93 |
| EPS Basic Continuous Ops | -0.79 | -0.46 | -0.49 | -0.62 | -0.94 |
| EPS Diluted Total Ops | -0.79 | -0.46 | -0.49 | -0.62 | -0.93 |
| EPS Diluted Continuous Ops | -0.79 | -0.46 | -0.49 | -0.62 | -0.94 |
| EBITDA(a) | $-85,229 | $-46,281 | $-50,044 | $-66,907 | $-88,909 |